Brief: Quantum Genomics H1 Operating Loss Widens To Eur 7.2 Mln

Quantum Genomics SA

06/10/2021 17:09

Oct 6 (Reuters) - Quantum Genomics SA  ALQGC.PA :
    * GROSS CASH OF €24.9 MILLION AT JUNE 30, 2021
    * 2021 HALF-YEAR RESULTS: CONTROLLED CASH FLOW OF €24.9
MILLION
    * H1 NET LOSS EUR 6.2 MILLION VERSUS LOSS EUR 5.1 MILLION
YEAR AGO
    * IN THE SECOND HALF OF 2021, QUANTUM GENOMICS SHOULD
RECEIVE ITS
FIRST MILESTONE PAYMENTS FOLLOWING THE EXPECTED INCLUSION OF THE
FIRST PATIENTS IN SOUTH KOREA AND TAIWAN IN REFRESH
    * H1 OPERATING LOSS EUR 7.2 MILLION VERSUS LOSS EUR 6.0
MILLION
YEAR AGO
    * AT THE END OF THE FIRST HALF OF 2021, THE COMPANY’S EQUITY
AMOUNTED TO €21.8 MILLION, PLUS €0.3 MILLION IN OTHER EQUITY
CAPITAL
    * FIRIBASTAT EXPECTED TO LAUNCH IN LATE 2023 FOR
DIFFICULT-TO-TREAT/RESISTANT HYPERTENSION

Source text for Eikon:  ID:nACT71353 
Further company coverage:  ALQGC.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))